Physician profile
Mark Vierra
NPI 1730187121
$2,624.65
in general payments reported to CMS, 2019-2025
19 companies · $561 in 2025
The $561 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $77.15 · 2021: $334 · 2022: $472 · 2023: $431 · 2024: $425 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065 · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.13 |
| Education | $351.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $963.77 | 2019-2025 | Tremfya |
| Abbvie INC. | $327.12 | 2019-2024 | Botox |
| Genzyme Corporation | $246.00 | 2022-2025 | |
| Amgen INC. | $189.82 | 2021-2023 | Otezla |
| Sanofi-Aventis U.S. LLC | $146.90 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $140.65 | 2021-2023 | |
| Vyne Pharmaceuticals INC. | $106.00 | 2020-2021 | |
| Almirall LLC | $77.08 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $70.87 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $66.36 | 2021 | |
| Incyte Corporation | $58.75 | 2024-2025 | Opzelura |
| Ucb, INC. | $46.36 | 2021-2025 | Bimzelx |
| Journey Medical Corporation | $43.42 | 2022-2025 | |
| Pfizer INC. | $34.64 | 2022-2024 | |
| Hill Dermaceuticals, INC. | $30.02 | 2025 | Tolak |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.20 | 2020-2023 | Arazlo, Jublia |
| Allergan, INC. | $24.00 | 2021 | |
| Prugen, INC. Pharmaceuticals | $16.22 | 2019 | |
| Organon LLC | $8.47 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vierra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.